Evidence map›Paper›PMID 35014837›Full record

ArticleACS applied bio materials2022

Antibody-Functionalized Carnauba Wax Nanoparticles to Target Breast Cancer Cells.

Banu Iyisan, Johanna Simon, Yuri Avlasevich, Stanislav Baluschev, Volker Mailaender, Katharina Landfester

Abstract read
In one paragraph

Article in ACS applied bio materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Solid phase wax coating ofRSC advances · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Banu IyisanMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.ORCID 0000-0003-3989-119X
Johanna SimonMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.
Yuri AvlasevichMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.
Stanislav BaluschevMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.ORCID 0000-0002-0742-0687
Volker MailaenderMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.
Katharina LandfesterMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.ORCID 0000-0001-9591-4638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of safer nanomedicines for drug delivery applications requires immense efforts to improve clinical outcomes. Targeting a specific cell, biocompatibility and biodegradability are vital properties of a nanoparticle to fulfill the safety criteria in medical applications. Herein, we fabricate antibody-functionalized carnauba wax nanoparticles encapsulated a hydrophobic drug mimetic, which is potentially interesting for clinical use due to the inert and nontoxic properties of natural waxes. The nanoparticles are synthesized applying miniemulsion methods by solidifying molten wax droplets and further evaporating the solvent from the dispersion. The pH-selective adsorption of antibodies (IgG1, immunoglobulin G1, and CD340, an antihuman HER2 antibody) onto the nanoparticle surface is performed for practical and effective functionalization, which assists to overcome the complexity in chemical modification of carnauba wax. The adsorption behavior of the antibodies is studied using isothermal titration calorimetry (ITC), which gives thermodynamic parameters including the enthalpy, association constant, and stoichiometry of the functionalization process. Both antibodies exhibit strong binding at pH 2.7. The CD340-decorated wax nanoparticles show specific cell interaction toward BT474 breast cancer cells and retain the targeting function even after 6 months of storage period.

Indexed as

Breast NeoplasmsNanoparticlesFemaleHumansImmunoglobulinsWaxescarnauba waxImmunoglobulinsWaxescancer targetingfunctionalizationisothermal titration calorimetrylipid nanoparticlesnanomedicine

Identifiers

PMID35014837
PMCPMC8864612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.